Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: margaret foley who wrote (19)	5/26/1998 10:22:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 1722

Margaret, from what I read from this and earlier news articles about this Indian company, is that they claimed they are using a "new process" of making the compound. It is apparent that there is no patent protection in SOME countries where patents and intellectual rights are not respected, e.g. there are 4 companies in China making a generic version of Prozac. No news on how Pfizer is dealing with this situation (in India).

To: margaret foley who wrote (19)	5/26/1998 6:06:00 PM
From: BUYandHOLD	Read Replies (1) \| Respond to of 1722

Margaret China, India and many South American countries don't appear to be affected by standard US Patents. These countries have routinely had knockoffs of major drugs (and other products) Ironically with per capita GDPs of $100-300/yr, patients in these countries would never have paid for these meds anyway, because of price. Still PFE execs go to bed wondering how wonderful life would be if they could sell to India (900mill), China (1 bill+) etc compared to a paltry 260 mill (US) or 55mill (UK) residents. Makes me wonder too.. CG